Claims for Patent: 11,376,262

Summary for Patent: 11,376,262

Title:	Method of treating an inflammatory or infectious disease
Abstract:	A method of treating an inflammatory or infectious disease includes administering an effective amount of pharmaceutical composition to a subject in need of treatment of the inflammatory or infectious disease. The composition includes an aqueous suspension of nanoparticles of a glucocorticosteroid compound.
Inventor(s):	Takahiro Tada, Kazuhiro Kagami, Kenta Kikuchi
Assignee:	Formosa Pharmaceuticals Inc
Application Number:	US16/732,173
Patent Claims:	1. A method of treating an eye inflammatory or infectious disease selected from the group consisting of blepharitis, blepharoconjunctivitis, meibomitis, acute or chronic stye, chalazion, dacryocystitis, dacryoadenitis, acne rosacea of eye lid, conjunctivitis, ophthalmia neonatorum, trachoma, corneal ulcer, superficial keratitis, interstitial keratitis, keratoconjunctivitis, foreign objects, post-surgery infections of cornea, endophthalmitis, infectious uveitis, and post-surgery infections of anterior chamber and uvea, and/or reducing likelihood of ophthalmia neonatorum or infections due to blepharoplasty, chalazion removal, blepharorrhaphy, surgeries for canaliculi and lacrimal drainage system, surgical treatments relating to eyelids and lacrimal apparatus, removal of pterygium, pinguecula or tumors, conjunctival transplant, external wounds, conjunctival flap surgery, removal of foreign objects, keratotomy and corneal transplant, photorefractive procedure, bleb filtration, anterior chamber paracentesis, iridotomy, cataract surgery, retinal surgery, or extraocular muscle relating surgeries, said method comprising administering a pharmaceutical composition comprising an aqueous suspension to a subject in need thereof in an effective amount, wherein the aqueous suspension comprises: nanoparticles of a glucocorticosteroid compound, wherein a mean particle diameter of the nanoparticles is 300 nm or less and a D90 particle diameter of the nanoparticles is 450 nm or less, and wherein the glucocorticosteroid compound is one or more substances selected from the group consisting of clobetasol propionate, diflorasone diacetate, dexamethasone propionate, difluprednate, mometasone furoate, diflucortolone valerate, betamethasone butyrate propionate, fluocinonide, hydrocortisone butyrate propionate, beclomethasone dipropionate, deprodone propionate, betamethasone valerate, dexamethasone valerate, prednisolone valerate acetate, fluocinolone acetonide, hydrocortisone butyrate, clobetasone butyrate, alclometasone dipropionate, triamcinolone acetonide, flumethasone pivalate, prednisolone and hydrocortisone; a physiologically acceptable salt; glycerin; hydrogenated soybean lecithin; and anhydrous citric acid. 2. The method of claim 1, wherein the nanoparticles are produced by mixing the glucocorticosteroid compound, the physiologically acceptable salt, glycerin, hydrogenated soybean lecithin and anhydrous citric acid. 3. The method of claim 2, wherein the nanoparticles are produced by further mixing with a surface modifier. 4. The method of claim 1, wherein the aqueous suspension further comprises a dispersion stabilizer. 5. The method of claim 4, the dispersion stabilizer is polyoxyethylene polyoxypropylene glycol and/or polyvinyl alcohol. 6. The method of claim 1, wherein the aqueous suspension further comprises a viscosity modifier. 7. The method of claim 6, the viscosity modifier is one or more substances selected from the group consisting of methyl cellulose, hydroxypropyl methylcellulose and polyvinyl alcohol. 8. The method of claim 6, wherein the aqueous suspension comprises 1 to 10 mg/mL of the viscosity modifier. 9. The method of claim 1, wherein the pharmaceutical composition is administered as an eye drop.